Stephanie Halene, MD, PhD

Assistant Professor of Medicine (Hematology)

Patient Care

Accepts new patients? No
Patient Type: Adult
Referrals: From physicians only

Patient Care Organizations


Cancer Center: Hematology Program

Yale Medicine

Office of Cooperative Research

Board Certifications

  • Hematology (Internal Medicine) AB of Internal Medicine (2006)

Clinical Trials

Conditions Study Title
Myeloid and Monocytic Leukemia, Pediatrics Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy
Leukemia, other A Phase I, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Leukemia, other A Phase I/II Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
Leukemia, other A Phase I-II Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
Myeloid and Monocytic Leukemia, Phase I A Phase I, Open-label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Acute Myeloid Leukemia and High-Risk Myelodsplastic Syndrome
Myeloid and Monocytic Leukemia, Phase I A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy With Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS
Leukemia, other A Phase III Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
Leukemia, other, Myeloid and Monocytic Leukemia Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy
Leukemia, other, Phase I A Phase I Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
Hodgkin's Lymphoma, Leukemia, other, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Hematopoietic, Phase I An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Myeloid and Monocytic Leukemia An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects
Myeloid and Monocytic Leukemia Selinexor (KPT-330) in Older Patients With Relapsed AML (SOPRA)
Leukemia, other Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Edit this profile

Contact Info

Stephanie Halene, MD, PhD
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street

New Haven, CT 06510
View on map...
Mailing Address
300 George St. 786
New Haven, CT 06511

Dysplastic human megakaryocyte